Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-2: Durvalumab with or without Bevacizumab as Adjuvant Therapy in HCC
NCT03847428Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 24
01
Overview
A Phase 3 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Apr 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03847428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847428.